CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to AVBP

furmonertinib 240 mg oral, daily

Phase 3
ArriVent BioPharma, Inc. (AVBP)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Metastatic Non-Small Cell Lung Cancer

View Full Landscape
Drug Information

Target Indication

Metastatic Non-Small Cell Lung Cancer

Clinical Trial

NCT05607550

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.